TheEdgeResearch
Home / Stocks / ANRO

Alto Neuroscience, Inc. (ANRO)

NYSE Healthcare Biotechnology
$28.78 ▲ +1.73%
Market Cap
$1.01B
Sector
Healthcare
Industry
Biotechnology
Beta
1.09
52-Wk Range
3.02-29.49
CEO
Amit Etkin
Country
US
Currency
USD

Alto Neuroscience, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Mountain View, CA, US. The stock last traded at $28.78, up 1.73% on the session, giving a market capitalisation of $1.01B. On trailing twelve-month figures it carries a trailing P/E of -11.60, a net margin of 0.0%. Its beta of 1.09 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-11.60
Price / Sales
0.00
Price / Book
3.89
EV / EBITDA
-10.55
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
0.02
Current ratio
20.52
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
New York Stock Exchange
Employees
68
IPO date
2024-02-02
Headquarters
Mountain View, CA, US
About Alto Neuroscience, Inc.

Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.

Comparable companies

Alto Neuroscience, Inc. is most often compared with the following Healthcare names:

ACIUALDXAMRNCLLSCTNMDBVTDRTSKRROLRMRSLN
More research on ANRO
ANRO technical analysis ANRO TheEdge Score Compare against peers
Open full interactive analysis & DCF →